U.S. News & World Report: Wegovy May Be Valuable New Option for Heart Failure Patients

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.

Now, injected Wegovy could prove a boon for many patients battling heart failure, a new study suggests. Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, was the lead author of the study and presented the results in Amsterdam at the annual meeting of the European Society of Cardiology (ESC).

Treatment with the drug “produced large improvements in symptoms, physical limitations and exercise function” compared to placebo, explained Dr. Kosiborod.

The study was published in the New England Journal of Medicine.

Read the full article from U.S. News & World Report: Wegovy May Be Valuable New Option for Heart Failure Patients